Healthcare · KIMS
Hospitals
from 796 today
KIMS delivered a strong Q1FY27 performance with robust top-line momentum driven by volume expansion and steady ramp-up of newly commissioned units, although initial incubation costs and higher finance expenses impacted margins and PAT.
Krishna Institute of Medical Sciences reported 16% YoY EBITDA growth, in line with our estimates, aided by reduced losses from Bengaluru units. We maintain a Buy rating with a target price of Rs850/share based on 30x FY28E EV/EBITDA.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
